+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Bovine Mastitis Market - Growth, Trends, and Forecasts (2023-2028)

  • PDF Icon

    Report

  • 115 Pages
  • April 2023
  • Region: Global
  • Mordor Intelligence
  • ID: 5394177
The bovine mastitis market is projected to register a CAGR of 5.1% during the forecast period.

The COVID-19 pandemic had an unprecedented impact on the growth of the bovine mastitis market. In 2020, it significantly impacted the supply chain of products for the treatment of bovine mastitis. Containment measures, such as lockdowns and social distancing, created problems in terms of the availability of medicines due to reduced operations in veterinary pharmacies. However, the relaxation of strict regulations post the pandemic led to the normal functioning of supply chain, which contributed to the market's growth.

The major factors responsible for the growth of the bovine mastitis market include the rising incidences of disease, the increasing product launches for animal healthcare, and technological advancements in the field of drug discovery and development.

Bovine mastitis is one of the major concerns in the dairy industry worldwide. Dairy farmers are facing huge economic losses with the rising incidences of cattle death globally. For instance, as per the data published by the MSD Manual in October 2022, severe mastitis caused by coliforms results in an higher incidence of cow death (30-50%) worldwide. These mortality rates in cows increase the direct and indirect costs, such as diagnostics, milk loss, veterinary services, labor, future milk production losses, and therapeutics. The rising bovine mastitis cases and related market loss are fuelling the demand for antibiotics in the treatment of the condition.

The increasing investments in the development of bovine mastitis treatment are expected to contribute to the market's growth. For instance, in August 2021, Stonehaven Incubates invested in the Anifera to conduct additional studies to explore the impact and effectiveness of adjunct therapy in bovine mastitis.

However, the rising threat of antibiotic resistance and a lack of awareness about the disease are expected to slow the market's growth over the forecast period.

Key Market Trends

Clinical Mastitis is Expected to Account for the Largest Market Share During the Forecast Period

The clinical mastitis segment is expected to hold a major share due to the high prevalence of clinical mastitis and the growing demand for effective therapeutics. According to a study published in the MDPI Journal in May 2021, the incidence of clinical mastitis in Southern Ethiopia was found to be 9%, 10%, and 10% in cows, camels, and goats, respectively, in 2020. Thus, the high prevalence of clinical mastitis is expected to drive the demand for effective therapeutics, thereby driving the growth of the segment.

The increasing R&D activities for the treatment of clinical mastitis are also expected to contribute to the growth of the segment. For instance, in January 2021, the Institute of Global Food Security at Queen's University launched a research project to tackle bovine clinical mastitis and reduce the broad spectrum of antibiotics in dairy cattle. This project was launched in partnership with AgriSearch and the Agri-Food and Biosciences Institutes (AFBI).

Thus, such factors are expected to contribute to the growth of the segment over the forecast period.



Asia-Pacific is Expected to Hold a Significant Share of the Market During the Forecast Period

Asia-Pacific is expected to hold a major share of the bovine mastitis market over the forecast period without significant fluctuations due to the strong adoption of intra-mammary infusion products for the treatment and the presence of leading players in the region.

The increasing incidence of bovine mastitis in the region is also expected to drive the growth of the market over the forecast period. For instance, according to the data published by Wageningen University and Research in 2022, the prevalence of subclinical mastitis among the cattle population in Sri Lanka, Bangladesh, India, and Pakistan ranged from about 20% to 80%. Such prevalence of bovine mastitis in Asia-Pacific is expected to drive the growth of the market in the region.

The adoption of advanced technologies in the region to manage bovine mastitis is also expected to contribute to the market's growth. For instance, in August 2021, Dairy Australia, Coles, Food Agility CRC, University of Sydney, University Technology Sydney, and Charles Sturt University collaborated to reduce the use of antibiotics in the milk supply chain and improve the health and management of dairy cows with mastitis. These organizations used the clinical mastitis decision support tool project, an AI-powered tool to manage clinical mastitis. Such developments are expected to contribute to the growth of the market in Asia-Pacific over the forecast period.



Competitive Landscape

The bovine mastitis market is moderately competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market, including Zoetis, Merck & Co. Inc, Boehringer Ingelheim, Bayer AG, Elanco, Ceva, and West Way Health.

Additional benefits of purchasing the report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support


This product will be delivered within 2 business days.

Table of Contents

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidence of the Disease
4.2.2 Increasing Product Launches for Animal Healthcare
4.2.3 Technological Advancements in the Field of Drug Discovery and Development
4.3 Market Restraints
4.3.1 Rising Threat of Antibiotic Resistance
4.3.2 Lack of Awareness About the Disease
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Type
5.1.1 Clinical Mastitis
5.1.2 Sub-clinical Mastitis
5.2 By Product
5.2.1 Antibiotics
5.2.2 Surgery
5.2.3 Vaccines
5.2.4 Pain Killers
5.2.5 Other Products
5.3 By Route of Administration
5.3.1 Intra-mammary
5.3.2 Systemic
5.4 By Therapy
5.4.1 Lactating Period
5.4.2 Dry Period
5.5 By End User
5.5.1 Hospitals and Clinics
5.5.2 Veterinary Centers
5.5.3 Other End Users
5.6 By Geography
5.6.1 North America
5.6.1.1 United States
5.6.1.2 Canada
5.6.1.3 Mexico
5.6.2 Europe
5.6.2.1 Germany
5.6.2.2 United Kingdom
5.6.2.3 France
5.6.2.4 Italy
5.6.2.5 Spain
5.6.2.6 Rest of Europe
5.6.3 Asia-Pacific
5.6.3.1 China
5.6.3.2 Japan
5.6.3.3 India
5.6.3.4 Australia
5.6.3.5 South Korea
5.6.3.6 Rest of Asia-Pacific
5.6.4 Middle East and Africa
5.6.4.1 GCC
5.6.4.2 South Africa
5.6.4.3 Rest of Middle East and Africa
5.6.5 South America
5.6.5.1 Brazil
5.6.5.2 Argentina
5.6.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Zoetis Inc.
6.1.2 Merck & Co. Inc.
6.1.3 Boehringer Ingelheim International GmbH
6.1.4 Elanco (Bayer AG)
6.1.5 Ceva
6.1.6 West Way Health
6.1.7 Norbrook
6.1.8 DeLaval
6.1.9 ImmuCell Corporation
6.1.10 Advanced Animal Diagnostics
6.1.11 Nimrod Veterinary Products Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Zoetis Inc.
  • Merck & Co. Inc.
  • Boehringer Ingelheim International GmbH
  • Elanco (Bayer AG)
  • Ceva
  • West Way Health
  • Norbrook
  • DeLaval
  • ImmuCell Corporation
  • Advanced Animal Diagnostics
  • Nimrod Veterinary Products Ltd

Methodology

Loading
LOADING...